The National Pharmaceutical Pricing Authority in its letter dated 3rd July 2020 has directed the manufactures to ensure the production of drug methyl prednisolone, enoxaparin, and dexamethasone in adequate quantity and to take proactive steps to maintain adequate stock and ensure supply across the country since these drugs are part of clinical treatment protocol of COVID-19.
The Manufacturers shall intimate the details regarding the production/sale of those drugs during the last two years and the details regarding the stock lying with the company. Further, they shall intimate the production schedule for next 6 months and details of suppliers to whom they are sourcing the above drugs and the details of procurement orders placed by the state government in the format enclosed.
Click here to read the notification.
